Medplus Health Services reported a 15-day drug license suspension for a subsidiary store by the FDA, with an estimated financial impact of ₹0.14 Crore.
Medplus Health Services reported a one-day drug license suspension at a Telangana store due to compliance violations. The estimated financial impact is Rs 0.001 Crore.
Medplus Health's subsidiary, Optival Health, received a 4-day drug license suspension at its Udala, Odisha store. The financial impact is estimated at Rs 0.02 Crore.
MedPlus Health Services reported a 7-day drug license suspension for its subsidiary Optival Health Solutions. The action carries an estimated financial impact of Rs 0.12 Crore.
Value
₹0.12 Cr
From
Assistant Director Drugs Control Administration, Mangalore Circle
The Food & Drug Administration suspended the drug license of a MedPlus subsidiary store in Nashik for 15 days. The expected financial impact is Rs 0.042 Crore.
MedPlus Health Services' subsidiary, Optival Health Solutions, received a one-day drug license suspension from the Drugs Control Administration for a store in Telangana due to non-compliance.
Medplus Health Services' subsidiary, Optival Health, received a 7-day drug license suspension in Andhra Pradesh and stay orders for previous suspensions in Maharashtra.
Medplus Health Services disclosed that regulatory authorities suspended the drug licenses of five subsidiary stores for 3 to 7 days. The expected financial impact is ₹0.10 Crore.
Medplus Health Services reported a 5-day suspension of a drug license at a Mangalore store due to compliance issues. The expected financial impact is ₹0.03 Crore.
MedPlus Health Services has filed board comments regarding a fine levied by the exchanges for non-compliance with Regulation 17(1A) of SEBI LODR Regulations, 2015.
